ReachMD CME

CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/differentiating-and-managing-pneumonitis-in-unresectable-stage-iii-nsclc-case-discussion/24393/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-consolidative-immunotherapy-in-unresectable-stage-iii-nsclc-case-discussion/24392/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/consolidative-immunotherapy-in-unresectable-stage-iii-nsclc-with-oncogenic-drivers/24391/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/immunotherapy-approaches-in-unresectable-stage-iii-nsclc-whats-on-the-horizon/24390/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/chemoradiotherapy-toxicities-how-do-they-impact-starting-immunotherapy/24389/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/consolidative-immunotherapy-following-scrt-vs-rt-only-in-stage-iii-nsclc/24388/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/consolidation-immunotherapy-after-concurrent-crt-what-do-real-world-data-show/24387/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/resolving-practice-barriers-to-consolidative-immunotherapy-in-stage-iii-nsclc/24386/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/accurate-staging-and-determining-resectability-in-nsclc/24385/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

CME credits: 0.50 Valid until: 14-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/safety-and-tolerability-of-changing-covalent-btk-inhibitor-treatment-in-a-patient-intolerant-to-ibrutinib-or-acalabrutinib/24454/ Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.

CME credits: 0.50 Valid until: 14-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/selection-of-btk-inhibitor-following-frontline-chemoimmunotherapy-in-older-patients-with-comorbidities/24453/ Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.

CME credits: 0.50 Valid until: 14-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/initial-btk-inhibitor-based-treatment-selection-in-a-treatment-naive-symptomatic-unfit-older-patient-with-comorbidities-and-high-risk-cytogenetics/24452/ Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.

CME credits: 0.50 Valid until: 09-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/optimal-sequencing-of-adcs-in-endocrine-refractory-hrher2-metastatic-breast-cancer/18104/ The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast cancer has greatly improved outcomes for patients in this setting. However, selecting the appropriate ADC and determining the optimal sequencing of these therapies may be challenging. In this activity, expert faculty in the field of breast cancer review the clinical burden related to endocrine-refractory disease, the role of ADCs in this setting, and best practices for the sequencing of these agents.

CME credits: 0.25 Valid until: 09-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/attr-cm-management-pearls-from-recent-clinical-trials-and-tailoring-therapy/18005/ Struggling to manage ATTR-CM? Our faculty are exploring the key considerations shaping current clinical trial design and how innovations might change our approach to the management of ATTR-CM in the future. They'll also discuss the use of outpatient diuretic intensification as a potential endpoint in trials and the ongoing challenge of defining and measuring “clinically meaningful benefit” for patients with ATTR-CM. Don't miss this opportunity to gain valuable insights and elevate your understanding of ATTR-CM treatment strategies!

CME credits: 1.00 Valid until: 06-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/are-two-pathways-better-than-one-experts-discuss-the-role-of-ang2-vegfa-inhibition-in-retinal-vascular-disease/16620/ Anti-vascular endothelial growth factor (VEGF) therapy acts on only 1 of the multiple pathways involved in the pathophysiology of retinal vascular diseases. Dual inhibition therapy that acts on 2 pathways—VEGF-A and angiopoietin-2 (Ang-2)—is now available. Are 2 pathways better than 1? Find out in this engaging roundtable-style eye care forum, which will demonstrate direct comparisons of dual anti-Ang-2/VEGF-A therapy and anti-VEGF monotherapy, enhanced by real-life case studies and anecdotes from the expert faculty members’ own practices.

CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/program-name/24359/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-immune-related-adverse-events-with-immunotherapies/24358/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/program-name/24357/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/current-and-emerging-biomarkers-of-response-to-immunotherapeutic-regimens/24356/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-immunotherapy-in-the-treatment-of-recurrent-or-metastatic-hnscc-the-evidence/24355/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.